A specific N-linked glycosylation inhibitor- tunicamycin can result in a reduction in the molecular weight of PD-L2 by approximately 15 kDa in two colorectal cancer (CRC) cell lines [71]. This evidence concerns the gene PDCD1LG2 and colorectal cancer.